CMA is a powerful analytical platform used to identify mechanisms and targets for the successful therapeutics to treat chronic pain
About
From initial study design to final data interpretation, INTiDYN is a proven biomedical research partner. We ensure our clients are asking the right questions and utilizing the most appropriate study designs—saving time and expense while delivering high-impact actionable data. The INTiDYN ChemoMorphometric Analysis (ITD-CMA) platform for comprehensive evaluation of complex tissues is helping companies of all sizes optimize the translation from basic research discoveries to clinical treatment options. Using a powerful analytical technique known as INTiDYN ChemoMorphic Analysis (ITD-CMA), INTiDYN evaluates tissue samples from animals or humans to create a morphological, biochemical, and genomic snapshot of normal conditions to compare with disease, or drug/toxin impacts on complex tissues. Interpretation of these analyses yields critical information about tissue transformations and molecular/cellular interactions, as well as the effects on the various functional systems integrated within a complex tissue (ie, cardiovascular, nervous, immune, endocrine), and every study is fully customized to the needs of our clients to ensure optimal results.
Key Benefits
1. Provides value in identifying quantitative normal and pathological molecular and structure mechanisms for the preclinical development and clinical testing primarily of chronic pain therapeutics. 2. Provides value in identifying inclusion/exclusion criteria and quantifiable therapeutic targets and endpoints to enhance successful clinical trials for chronic pain therapeutics. 3. Provide value for making go/no-go decisions for all phases of therapeutic development ranging from preclinical non-human and human discovery through Phase 1-3 clinical trials
Applications
Development of therapeutics to treat peripheral neuropathies, dermatopathologies, and vasculopathies especially those related to chronic pain, itch, and vascular and metabolic dysregulations.